comparemela.com
Home
Live Updates
280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting : comparemela.com
280Bio Provides Update on the KRAS Inhibitor TEB-17231 at the 2023 AACR Annual Meeting
280Bio, Inc. a clinical stage biotechnology company, focused on the development of precision oncology medicines, today announced a presentation featuring the Company's lead development
Related Keywords
Houston
,
Texas
,
United States
,
China
,
Florida
,
Shanghai
,
Orlando
,
Yingli Pharma
,
Xu Zusheng
,
Michael Hui
,
Head Of Research
,
Shanghai Yingli Pharmaceutical Co Ltd
,
Development Of Yingli Pharma
,
Md Anderson Cancer Center
,
Bio Inc
,
Session Category
,
Cellular Biology
,
Session Title
,
Ras Related Signaling
,
Monday April
,
Poster Board
,
Cancer Center
,
General Manager
,
San Francisco Bay Area
,
280bio
,
Acrmeeting
,
Ealth Press Release
,
comparemela.com © 2020. All Rights Reserved.